ADVFN Logo ADVFN
Donnée du Marché
Actualité
Outils
Donnée du Marché
Discover

Hot Features

Follow Feed

Rester connecter avec les traders et investisseurs dans notre communauté Follow Feed.

Flux des Options

Explorez des données complètes sur les options et utilisez les filtres avancés avec Options Flow.

Moniteur

Organisez et surveillez vos d'actions et actifs avec le Moniteur.
Se connecter Premium IconPremium Help Menu
CAC 40
8 087,46
0,59%
Dow Jones
38 239,98
0,00%
DAX
18 065,46
1,20%
Brent Oil
85,765
-0,75%
Bitcoin
66 133,71
-1,08%
Registration Strip Icon for default Inscrivez-vous gratuitement pour obtenir des cotations en temps réel, des graphiques interactifs, un flux d'options en direct et plus encore.
S'inscrire
  1. Accueil
  2. Investir
  3. Actions
  4. Etats-Unis
  5. NYSE
  6. Merck and Co Inc (MRK)

  7. Merck and Co Inc (MRK) Actualités

MRK Merck and Co Inc

127,38
0,44 (0,35%)
Avant marché
Dernière mise à jour : 14:48:38
Retardé de 15 minutes
Nom Action Symbole Action Marché Type
Merck and Co Inc MRK NYSE Action ordinaire
  Variation Action Variation Action% Cours Dernier Dernier échange
Upgrade Icon
0,44 0,35% 127,38 14:48:38
Ouverture Plus Bas Plus Haut Prix de clôture Clôture Veille
126,94
plus d'informations sur les cotations »

Actualités Recentes

Date Heure Source Titre
19/4/202413:04PRNCASanté Canada approuve KEYTRUDA® comme traitement de première..
10/4/202413:13IHMARKETNEWSDelta Generates US$37 Million Profit in Q1, Google and Intel..
04/4/202412:45BWMerck Initiates Phase 3 Clinical Trial of MK-1084, an..
03/4/202414:00BWREJOICE-Ovarian01 Phase 2/3 Trial of Raludotatug Deruxtecan..
01/4/202412:45BWMerck to Hold First-Quarter 2024 Sales and Earnings..
28/3/202411:45BWEuropean Commission Approves Merck’s KEYTRUDA®..
27/3/202411:54IHMARKETNEWSGameStop Shares Tumble 20% in Pre-Market Trading Amid..
26/3/202423:21BWFDA Approves Merck’s WINREVAIR™ (sotatercept-csrk), a..
21/3/202411:45BWMerck Provides Update on Phase 3 KEYLYNK-006 Trial..
19/3/202414:00BWMerck Announces Positive Data on V116, an Investigational,..
15/3/202421:23PRNUSFarmSee Ltd Announces the Completion of a Minority..
15/3/202411:45BWMerck’s KEYTRUDA® (pembrolizumab) Plus Chemoradiotherapy..
13/3/202408:00BWMerck Announces Plans to Conduct Clinical Trials of a Novel..
11/3/202413:15BWMerck Completes Acquisition of Harpoon Therapeutics, Inc.
06/3/202416:25BWGilead and Merck Announce Phase 2 Data Showing an..
05/3/202415:03IHMARKETNEWSFutures Pointing To Continued Weakness On Wall Street
05/3/202412:45BWMerck to Participate in the Barclays 26th Annual Global..
04/3/202412:45BWMerck to Participate in the Leerink Partners Global..
27/2/202412:45BWMerck to Participate in the TD Cowen 44th Annual Health Care..
23/2/202412:20BWMerck Receives Positive EU CHMP Opinion for KEYTRUDA®..
20/2/202422:14EDGAR2Form 8-K - Current report
20/2/202412:45BWFDA Grants Priority Review to Merck's Application for..
15/2/202422:03EDGAR2Form 4 - Statement of changes in beneficial ownership of..
15/2/202422:01EDGAR2Form 4 - Statement of changes in beneficial ownership of..
14/2/202422:40EDGAR2Form 144 - Report of proposed sale of securities
14/2/202422:30EDGAR2Form 144 - Report of proposed sale of securities
14/2/202422:24EDGAR2Form 144 - Report of proposed sale of securities
13/2/202422:50EDGAR2Form 144 - Report of proposed sale of securities
13/2/202422:48EDGAR2Form 144 - Report of proposed sale of securities
12/2/202422:03EDGAR2Form 4 - Statement of changes in beneficial ownership of..
12/2/202413:05PRNCASanté Canada approuve KEYTRUDA®, en association avec le..
09/2/202422:06EDGAR2Form 144 - Report of proposed sale of securities
08/2/202422:04EDGAR2Form 4 - Statement of changes in beneficial ownership of..
08/2/202413:00PRNCAMERCK CANADA ANNOUNCES COLLABORATION WITH VECTOR INSTITUTE..
07/2/202422:09EDGAR2Form 144 - Report of proposed sale of securities
05/2/202422:01EDGAR2Form 4 - Statement of changes in beneficial ownership of..
05/2/202412:33PRNUSElanco Announces Sale of Aqua Business for $1.3 Billion
02/2/202422:35EDGAR2Form 144 - Report of proposed sale of securities
02/2/202422:09EDGAR2Form 144 - Report of proposed sale of securities
02/2/202422:08EDGAR2Form 144 - Report of proposed sale of securities
02/2/202422:07EDGAR2Form 4 - Statement of changes in beneficial ownership of..
02/2/202422:05EDGAR2Form 4 - Statement of changes in beneficial ownership of..
01/2/202412:39EDGAR2Form 8-K - Current report
01/2/202412:30BWMerck Announces Fourth-Quarter and Full-Year 2023 Financial..
27/1/202416:00BWMerck’s KEYTRUDA® (pembrolizumab) Reduced the Risk of Death..
26/1/202417:49EDGAR2Form SC 13G/A - Statement of acquisition of beneficial..
26/1/202416:00BWMerck’s KEYTRUDA® (pembrolizumab) Significantly Improved..
25/1/202414:07DJNLava Therapeutics Shares Rise as Drug Set for Test With..
24/1/202422:17EDGAR2Form 4 - Statement of changes in beneficial ownership of..
24/1/202422:16EDGAR2Form 4 - Statement of changes in beneficial ownership of..

Dernières Valeurs Consultées

NYSE
MRK
Merck
Delayed Upgrade Clock
ADVFN Logo

France
Société
Entreprise
Popular
Obtenir l'application

Assistance: support@advfn.fr

En accédant aux services disponibles de ADVFN, vous acceptez les Conditions Générales de ADVFN Conditions Générales

© 2024 ADVFN PLC - Tous droits réservés